CoChat
Sign Up
Cited by 430

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Targeting folate receptor alpha for cancer treatment

Cheung, Anthony, Bax, Heather J., Josephs, Debra H., Ilieva, Kristina M., Pellizzari, Giulia, Opzoomer, James, Bloomfield, Jacinta, Fittall, Matthew, Grigoriadis, Anita, Figini, Mariangela, Canevari, Silvana, Spicer, James F., Tutt, Andrew N., Karagiannis, Sophia N.·2016·Oncotarget
DOI 10.18632/oncotarget.9651PMC PMC5239573
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.9651

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 137

  1. Locasale, 2013, Serine, glycine and one-carbon units: cancer metabolism in full circle, Nat Rev Cancer, 13, 572, 10.1038/nrc3557 · DOI
  2. Daval, 2013, Folate and fetal programming: a play in epigenomics?, Trends Endocrinol Metab, 24, 279, 10.1016/j.tem.2013.01.010 · DOI
  3. Daval, 2013, Early methyl donor deficiency may induce persistent brain defects by reducing Stat3 signaling targeted by miR-124, Cell Death Dis, 4, e755, 10.1038/cddis.2013.278 · DOI
  4. Smulders, 2011, Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects, J Inherit Metab Dis, 34, 75, 10.1007/s10545-010-9177-4 · DOI
  5. Goldman, 2003, Membrane transport of folates, Vitam Horm, 66, 403, 10.1016/S0083-6729(03)01012-4 · DOI
  6. Goldman, 2011, Mechanisms of membrane transport of folates into cells and across epithelia, Annu Rev Nutr, 31, 177, 10.1146/annurev-nutr-072610-145133 · DOI
  7. Thigpen, 2015, Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments, Ann Oncol, 26, 2034, 10.1093/annonc/mdv250 · DOI
  8. Ratnam, 2007, The folate receptor: what does it promise in tissue-targeted therapeutics?, Cancer Metastasis Rev, 26, 141, 10.1007/s10555-007-9048-0 · DOI
  9. Kelemen, 2006, The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?, Int J Cancer, 119, 243, 10.1002/ijc.21712 · DOI
  10. Boiocchi, 1997, Overexpression of folate binding protein in ovarian cancers, Int J Cancer, 74, 193, 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F · DOI
  11. Wang, 2015, A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer, Drug Des Devel Ther, 9, 4989, 10.2147/DDDT.S90670 · DOI
  12. Vahrmeijer, 2016, Concordance of folate receptor-alpha expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients, Oncotarget, 10.18632/oncotarget.7856 · DOI
  13. Fu, 2012, Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease, Springerplus, 1, 22, 10.1186/2193-1801-1-22 · DOI
  14. Cheung, 2012, Paradoxical impact of two folate receptors, FRalpha and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome, PLoS One, 7, e47201, 10.1371/journal.pone.0047201 · DOI
  15. Lacey, 1995, Folate receptors targeted to clathrin-coated pits cannot regulate vitamin uptake, Proc Natl Acad Sci U S A, 92, 3824, 10.1073/pnas.92.9.3824 · DOI
  16. Anderson, 1990, The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway, J Cell Biol, 110, 637, 10.1083/jcb.110.3.637 · DOI
  17. Mayor, 2004, Folate receptor endocytosis and trafficking, Adv Drug Deliv Rev, 56, 1099, 10.1016/j.addr.2004.01.010 · DOI · Paper page
  18. Mayanil, 2012, Nuclear localization of folate receptor alpha: a new role as a transcription factor, Sci Rep, 2, 980, 10.1038/srep00980 · DOI
  19. Canevari, 2003, Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies, Gene Ther, 10, 1018, 10.1038/sj.gt.3301962 · DOI
  20. Potet, 1997, Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases, Hum Pathol, 28, 922, 10.1016/S0046-8177(97)90007-1 · DOI
  21. Miotti, 2003, A step further in understanding the biology of the folate receptor in ovarian carcinoma, Gynecol Oncol, 88, S140, 10.1006/gyno.2002.6705 · DOI
  22. del Pozo, 2009, The absence of caveolin-1 increases proliferation and anchorage- independent growth by a Rac-dependent, Erk-independent mechanism, Mol Cell Biol, 29, 5046, 10.1128/MCB.00315-09 · DOI
  23. Knutson, 2009, Functional folate receptor alpha is elevated in the blood of ovarian cancer patients, PLoS One, 4, e6292, 10.1371/journal.pone.0006292 · DOI
  24. Martensen, 2015, Folic acid mediates activation of the pro-oncogene STAT3 via the Folate Receptor alpha, Cell Signal, 27, 1356, 10.1016/j.cellsig.2015.03.020 · DOI
  25. Canevari, 2000, Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1, J Cell Sci, 113, 349
  26. Daly, 2013, Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway, Cancer Res, 73, 1969, 10.1158/0008-5472.CAN-12-1472 · DOI
  27. Hartmann, 2008, Folate receptor alpha as a tumor target in epithelial ovarian cancer, Gynecol Oncol, 108, 619, 10.1016/j.ygyno.2007.11.020 · DOI
  28. Coleman, 2015, Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications, Cancer Metastasis Rev, 34, 41, 10.1007/s10555-014-9539-8 · DOI
  29. Leamon, 2005, Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay, Anal Biochem, 338, 284, 10.1016/j.ab.2004.12.026 · DOI
  30. Ratnam, 1994, Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications, Cancer, 73, 2432, 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S · DOI
  31. Jackman, 2007, Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells, Cytometry A, 71, 945
  32. Colnaghi, 1987, Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity, Int J Cancer, 39, 297, 10.1002/ijc.2910390306 · DOI
  33. Roos, 1993, Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients, Cancer Res, 53, 5413
  34. Ratnam, 2004, Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy, Adv Drug Deliv Rev, 56, 1067, 10.1016/j.addr.2004.01.001 · DOI
  35. Kularatne, 2009, Folate-targeted therapeutic and imaging agents for cancer, Curr Opin Chem Biol, 13, 256, 10.1016/j.cbpa.2009.03.022 · DOI
  36. Low, 2008, Tumor detection using folate receptor-targeted imaging agents, Cancer Metastasis Rev, 27, 655, 10.1007/s10555-008-9155-6 · DOI
  37. Low, 2003, Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects, J Control Release, 91, 17, 10.1016/S0168-3659(03)00215-3 · DOI
  38. Cheng, 2012, Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response, Mol Oncol, 6, 360, 10.1016/j.molonc.2011.11.010 · DOI
  39. Murphy, 2015, New perspectives on targeted therapy in ovarian cancer, Int J Womens Health, 7, 189
  40. Vergote, 2013, Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy, Gynecol Oncol, 130, 192, 10.1016/j.ygyno.2013.03.024 · DOI
  41. Bart, 2012, The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer, Cell Oncol (Dordr), 35, 9
  42. Low, 2013, Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents, Arch Pathol Lab Med, 137, 241, 10.5858/arpa.2012-0176-OA · DOI
  43. Miyahara, 2008, Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers, Ann Surg Oncol, 15, 889, 10.1245/s10434-007-9755-3 · DOI
  44. Wistuba, 2012, High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation, J Thorac Oncol, 7, 833, 10.1097/JTO.0b013e31824de09c · DOI
  45. Vachani, 2012, Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance, Oncotarget, 3, 414, 10.18632/oncotarget.489 · DOI
  46. Sugarbaker, 2001, The alpha folate receptor is highly activated in malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 121, 225, 10.1067/mtc.2001.111176 · DOI
  47. Lunec, 2010, The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy, Br J Cancer, 102, 553, 10.1038/sj.bjc.6605501 · DOI
  48. Low, 2007, Folate receptor overexpression is associated with poor outcome in breast cancer, Int J Cancer, 121, 938, 10.1002/ijc.22811 · DOI
  49. Ballman, 2015, Correction: Folate receptor-alpha (FOLR1) expression and function in triple negative tumors, PLoS One, 10, e0127133, 10.1371/journal.pone.0127133 · DOI
  50. Ballman, 2015, Folate receptor-alpha (FOLR1) expression and function in triple negative tumors, PLoS One, 10, e0122209, 10.1371/journal.pone.0122209 · DOI
  51. Tang, 2014, Folate receptor alpha associated with triple-negative breast cancer and poor prognosis, Arch Pathol Lab Med, 138, 890, 10.5858/arpa.2013-0309-OA · DOI
  52. Ratnam, 2003, Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting, Cancer Res, 63, 2820
  53. Carey, 2009, Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer, Clin Breast Cancer, 9, S73
  54. Carey, 2010, Directed therapy of subtypes of triple-negative breast cancer, Oncologist, 15, 49, 10.1634/theoncologist.2010-S5-49 · DOI
  55. Waneck, 1992, Glycosyl-phosphatidylinositol-anchored membrane proteins, J Am Soc Nephrol, 3, 895, 10.1681/ASN.V34895 · DOI
  56. Fujiwara, 2016, Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression, Int J Cancer, 138, 1994, 10.1002/ijc.29937 · DOI
  57. Colnaghi, 1994, Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19, Eur J Cancer, 30A, 363
  58. Marcucci, 2013, Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4, J Ovarian Res, 6, 29, 10.1186/1757-2215-6-29 · DOI
  59. Seccamani, 1991, Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody, Eur J Cancer, 27, 724, 10.1016/0277-5379(91)90174-C · DOI
  60. Kenemans, 2001, Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p, Int J Cancer, 92, 106, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1145>3.0.CO;2-I · DOI
  61. Green, 2004, Folate-receptor-targeted radionuclide imaging agents, Adv Drug Deliv Rev, 56, 1143, 10.1016/j.addr.2004.01.004 · DOI
  62. Gershenson, 2003, Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results, J Nucl Med, 44, 700
  63. Douglas, 2002, Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical, Bioconjug Chem, 13, 1200, 10.1021/bc0200430 · DOI
  64. Wiener, 2000, Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress, Invest Radiol, 35, 50, 10.1097/00004424-200001000-00006 · DOI
  65. Daldrup-Link, 2010, Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133, Radiology, 255, 527, 10.1148/radiol.10090050 · DOI
  66. Weber, 2014, Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging, J Nucl Med, 55, 701, 10.2967/jnumed.113.133074 · DOI
  67. Omote, 2015, Phase I clinical trial of 99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults, Ann Nucl Med, 29, 792, 10.1007/s12149-015-1006-2 · DOI
  68. Leamon, 2007, Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate, Cancer Res, 67, 6376, 10.1158/0008-5472.CAN-06-3894 · DOI
  69. Leamon, 2006, Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide, Bioorg Med Chem Lett, 16, 5093, 10.1016/j.bmcl.2006.07.030 · DOI
  70. Cattel, 2010, EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers, Curr Opin Investig Drugs, 11, 1424
  71. Edelman, 2012, EC145: a novel targeted agent for adenocarcinoma of the lung, Expert Opin Investig Drugs, 21, 755, 10.1517/13543784.2012.671294 · DOI
  72. Sausville, 2012, Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors, J Clin Oncol, 30, 4011, 10.1200/JCO.2011.41.4946 · DOI
  73. Garon, 2012, Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung, J Thorac Oncol, 7, 1618, 10.1097/JTO.0b013e318267d051 · DOI
  74. Harb, 2014, Target: A randomized, phase II trial comparing vintafolide versus vintafolide plus docetaxel, versus docetaxel alone in second line treatment of folate-receptor-positive non-small cell lung cancer (NSCLC) patients, Annals of Oncology, 25, v1, 10.1093/annonc/mdu438.48 · DOI
  75. Symanowski, 2013, PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer, J Clin Oncol, 31, 4400, 10.1200/jco.2013.31.15_suppl.5572 · DOI
  76. Merck Press Release. Merck and endocyte announce independent dsmb recommends vintafolide proceed phase 3 trial be stopped for futility following interim analysis. 2014. Available from: http://investor.endocyte.com/releasedetail.cfm?ReleaseID=844838.
  77. Messmann, 2010, A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle, J Clin Oncol, 28, 3082, 10.1200/jco.2010.28.15_suppl.3082 · DOI
  78. Rinaldi, 2013, Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent, Drug Dev Ind Pharm, 39, 1315, 10.3109/03639045.2012.728226 · DOI
  79. Alland, 2015, A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors, Invest New Drugs, 33, 321, 10.1007/s10637-014-0171-9 · DOI
  80. Sausville, 2011, Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications, J Pharmacol Exp Ther, 336, 336, 10.1124/jpet.110.175109 · DOI
  81. Gibson, 2003, Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies, Bioconjug Chem, 14, 563, 10.1021/bc025642l · DOI
  82. Fuchs, 2002, Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics, Bioorg Med Chem, 10, 2397, 10.1016/S0968-0896(02)00019-6 · DOI
  83. Leamon, 2009, In vivo structural activity and optimization studies of folate-tubulysin conjugates, Mol Pharm, 6, 1518, 10.1021/mp900086w · DOI
  84. Natsugoe, 2012, Clinical significance of folate receptor beta-expressing tumor-associated macrophages in pancreatic cancer, Ann Surg Oncol, 19, 2264, 10.1245/s10434-012-2263-0 · DOI
  85. Matsuyama, 2009, Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta, Cancer Immunol Immunother, 58, 1577, 10.1007/s00262-009-0667-x · DOI
  86. Xiao, 2013, Anti-tumour strategies aiming to target tumour-associated macrophages, Immunology, 138, 93, 10.1111/imm.12023 · DOI
  87. Low, 2009, A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages, Blood, 113, 438, 10.1182/blood-2008-04-150789 · DOI
  88. Amato, 2008, Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors, J Nucl Med, 49, 899, 10.2967/jnumed.107.049478 · DOI
  89. Gibbs, 2004, Antifolates targeted specifically to the folate receptor, Adv Drug Deliv Rev, 56, 1111, 10.1016/j.addr.2004.01.003 · DOI
  90. Matherly, 2015, 6-Substituted Pyrrolo [23-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor alpha and the Proton-Coupled Folate Transporter in Human Tumors, J Med Chem, 58, 6938, 10.1021/acs.jmedchem.5b00801 · DOI
  91. Jackman, 2003, Selective delivery of CB300638, a cyclopenta [g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor, Cancer Res, 63, 3612
  92. Jackman, 2005, BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors, Cancer Res, 65, 11721, 10.1158/0008-5472.CAN-05-2034 · DOI
  93. Aboagye, 2008, Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945, Cancer Res, 68, 3827, 10.1158/0008-5472.CAN-08-0135 · DOI
  94. Kuhn, 2007, Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer, Lancet Oncol, 8, 451, 10.1016/S1470-2045(07)70142-0 · DOI
  95. Low, 2013, A phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma, J Immunother, 36, 268, 10.1097/CJI.0b013e3182917f59 · DOI · Paper page
  96. McFadden, 2012, Oncolytic virotherapy for ovarian cancer, Oncolytic Virother, 1, 1, 10.2147/OV.S31626 · DOI
  97. Peng, 2006, The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer, Clin Cancer Res, 12, 6170, 10.1158/1078-0432.CCR-06-0992 · DOI
  98. Grasso, 2007, Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha, Cancer Immun, 7, 6
  99. Smith, 2012, Farletuzumab, an anti-folate receptor alpha antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro, Cancer Chemother Pharmacol, 70, 113, 10.1007/s00280-012-1890-2 · DOI
  100. Hassan, 2013, Farletuzumab in lung cancer, Lung Cancer, 80, 15, 10.1016/j.lungcan.2012.12.021 · DOI
  101. Grasso, 2013, The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity, Cancer Biol Ther, 14, 1032, 10.4161/cbt.26106 · DOI
  102. Sood, 2015, Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer, Clin Cancer Res, 21, 448, 10.1158/1078-0432.CCR-14-1578 · DOI
  103. Old, 2010, Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study, Clin Cancer Res, 16, 5288, 10.1158/1078-0432.CCR-10-0700 · DOI
  104. Alvarez, 2016, Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer, Gynecol Oncol, 140, 210, 10.1016/j.ygyno.2015.11.031 · DOI
  105. Coleman, 2013, Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer, Gynecol Oncol, 129, 452, 10.1016/j.ygyno.2013.03.002 · DOI
  106. Benedetti Panici, 2014, Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review, Onco Targets Ther, 7, 1223
  107. Zurawski, 1994, Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing, Cancer Res, 54, 2448
  108. Bombardieri, 1995, Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer, Eur J Cancer, 31A, 686
  109. Verheijen, 1997, Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study, Cancer, 80, 2712, 10.1002/(SICI)1097-0142(19971215)80:12+<2712::AID-CNCR50>3.0.CO;2-B · DOI
  110. Corstens, 1998, Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration, Eur J Nucl Med, 25, 1552, 10.1007/s002590050335 · DOI
  111. Matzku, 1991, Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: analysis of cell binding and internalization, Int J Cancer, 48, 284, 10.1002/ijc.2910480222 · DOI
  112. Verheijen, 2002, Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study, J Cancer Res Clin Oncol, 128, 484, 10.1007/s00432-002-0348-z · DOI
  113. Tedesco, 2006, Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma, Cancer Res, 66, 3876, 10.1158/0008-5472.CAN-05-3434 · DOI
  114. Canevari, 1998, Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection, Cancer Res, 58, 991
  115. Powell, 2015, Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor, Oncotarget, 6, 28911, 10.18632/oncotarget.5029 · DOI
  116. Griffiths, 1994, In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation, J Mol Biol, 239, 68, 10.1006/jmbi.1994.1351 · DOI
  117. Canevari, 2009, Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor, Cancer Immunol Immunother, 58, 531, 10.1007/s00262-008-0575-5 · DOI
  118. Canevari, 2011, Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5. 3 in a mouse model for ovarian cancer, J Nucl Med, 52, 1938, 10.2967/jnumed.110.086819 · DOI
  119. Korngold, 1999, Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma, Eur J Immunol, 29, 3527, 10.1002/(SICI)1521-4141(199911)29:11<3527::AID-IMMU3527>3.0.CO;2-5 · DOI
  120. Gould, 2012, Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application, Cancer Immunol Immunother, 61, 1547, 10.1007/s00262-011-1162-8 · DOI
  121. Gould, 2008, Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells, Cancer Immunol Immunother, 57, 247
  122. Gould, 2007, IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells, J Immunol, 179, 2832, 10.4049/jimmunol.179.5.2832 · DOI
  123. Gould, 2003, Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells, Eur J Immunol, 33, 1030, 10.1002/eji.200323185 · DOI
  124. Karagiannis, 2007, Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis, J Immunol Methods, 323, 160, 10.1016/j.jim.2007.04.009 · DOI
  125. Karagiannis, 2014, Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency, MAbs, 6, 509, 10.4161/mabs.27828 · DOI
  126. Corrigan, 2011, Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcvarepsilonRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity, Clin Exp Allergy, 41, 1400, 10.1111/j.1365-2222.2011.03770.x · DOI
  127. Karagiannis, 2014, IgE immunotherapy: a novel concept with promise for the treatment of cancer, MAbs, 6, 54, 10.4161/mabs.27029 · DOI · Paper page
  128. Karagiannis, 2015, Tumour-associated macrophage polarisation and re-education with immunotherapy, Front Biosci (Elite Ed), 7, 293
  129. Lamers, 1995, Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody, J Natl Cancer Inst, 87, 1463, 10.1093/jnci/87.19.1463 · DOI
  130. Hwu, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin Cancer Res, 12, 6106, 10.1158/1078-0432.CCR-06-1183 · DOI
  131. Canevari, 1999, Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival, Int J Cancer, 84, 62, 10.1002/(SICI)1097-0215(19990219)84:1<62::AID-IJC12>3.0.CO;2-T · DOI
  132. Powell, 2011, In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB), Cancer Res, 71, 4617, 10.1158/0008-5472.CAN-11-0422 · DOI
  133. Ribas, 2015, Releasing the Brakes on Cancer Immunotherapy, N Engl J Med, 373, 1490, 10.1056/NEJMp1510079 · DOI
  134. Konishi, 2016, Immune checkpoint inhibition in ovarian cancer, Int Immunol
  135. Brahmer, 2016, Immune Checkpoint Therapy in Non-Small Cell Lung Cancer, Cancer J, 22, 81, 10.1097/PPO.0000000000000178 · DOI
  136. Bianchini, 2016, New Strategies in Breast Cancer: Immunotherapy, Clin Cancer Res, 22, 2105, 10.1158/1078-0432.CCR-15-1315 · DOI
  137. Jazaeri, 2016, Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies, Cancer J, 22, 101, 10.1097/PPO.0000000000000179 · DOI

Cited by

Sorted by citations

See all 430

Metadata

Authors
Cheung, A., Bax, H. J., Josephs, D. H., Ilieva, K. M., Pellizzari, G., Opzoomer, J., Bloomfield, J., Fittall, M., Grigoriadis, A., Figini, M., Canevari, S., Spicer, J. F., Tutt, A. N., & Karagiannis, S. N.
Affiliations
  • St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London & NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London, Guy's Hospital, King's College London, London, United Kingdom
  • Breast Cancer Now Research Unit, Faculty of Life Sciences and Medicine, Guy's Hospital, King's College London, London, United Kingdom
  • Unit of Molecular Therapies, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • Division of Cancer Studies, Faculty of Life Sciences and Medicine, Guy's Hospital, King's College London, London, United Kingdom
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2016-05-27
Volume
7
Issue
32
Pages
52553-52574
ISSN
1949-2553
DOI
10.18632/oncotarget.9651
PMC
PMC5239573
Cited by
430
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review